Table III.
Univariate analysis of the prognostic factors for PFS and OS.
| Prognostic factors | Cases | PFS | OS |
|---|---|---|---|
| Gender | |||
| Male | 18 | ||
| Female | 9 | 0.566 | 0.320 |
| Age (years) | |||
| ≥55 | 9 | ||
| <55 | 18 | 0.325 | 0.167 |
| Genotype | |||
| IgA+IgD | 13 | ||
| Other | 14 | 0.885 | 0.183 |
| β2-MG (mg/l) | |||
| ≥5.5 | 13 | ||
| <5.5 | 14 | 0.105 | 0.211 |
| Chromosome | |||
| Abnormal | 5 | ||
| Normal | 22 | 0.801 | 0.652 |
| Induction chemotherapy | |||
| Traditional | 12 | ||
| Bortezomib | 15 | 0.626 | 0.524 |
| Before transplantation | |||
| Without CR | 20 | ||
| With CR | 7 | 0.476 | 0.460 |
| Refractory or relapsed | |||
| Yes | 7 | ||
| No | 20 | 0.174 | 0.138 |
| Time span of transplantation and diagnosis (months) | |||
| >6 | 11 | ||
| <6 | 16 | 0.563 | 0.743 |
| Conditioning regimen | |||
| HDM | 11 | ||
| Bortezomib+HDM | 16 | 0.471 | 0.219 |
| CD34+ count (/kg) | |||
| <3×106 | 15 | ||
| ≥3×106 | 12 | 0.767 | 0.586 |
| Efficacy after transplantation | |||
| Without CR | 8 | ||
| With CR | 20 | 0.157 | 0.289 |
| Maintenance treatment | |||
| No | 8 | ||
| Yes | 19 | 0.010 | 0.008 |
| Overall treatment | |||
| No | 13 | ||
| Yes | 14 | 0.010 | 0.106 |
PFS, progression free survival; OS, overall survival; HDM: high-dose melphalan; CR, complete remission; β2-MG, β2-microglobulin.